MDT logo

MDT
Medtronic Plc

10,729
Mkt Cap
$100.91B
Volume
7.05M
52W High
$106.33
52W Low
$74.40
PE Ratio
21.94
MDT Fundamentals
Price
$78.60
Prev Close
$78.15
Open
$78.40
50D MA
$83.18
Beta
0.43
Avg. Volume
8.66M
EPS (Annual)
$3.61
P/B
2.06
Rev/Employee
$353,021.05
$129,450.98
Loading...
Loading...
News
all
press releases
Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?
Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.
News Placeholder
More News
News Placeholder
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain PR Newswire GALWAY, Ireland, May 20, 2026 Acquisition...
News Placeholder
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
News Placeholder
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
The latest trading day saw Medtronic (MDT) settling at $77.32, representing a +1.54% change from its previous close.
News Placeholder
Boston Scientific Bets on Growth Through Strategic M&A Deals
BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.
News Placeholder
Here's How Boston Scientific Is Expanding Its Global Growth
BSX expands global reach with strong APAC growth, FARAPULSE momentum and new approvals driving gains across Europe and China.
News Placeholder
FitLife Brands Inc. (FTLF) Surpasses Q1 Earnings Estimates
FitLife Brands (FTLF) delivered earnings and revenue surprises of +21.43% and -1.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Prestige Consumer Healthcare (PBH) Q4 Earnings and Revenues Lag Estimates
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -11.72% and -4.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.
News Placeholder
Intuitive Surgical Trades Near 2-Year Low: Is $600 Within Reach?
ISRG nears a key support level after a 23.7% YTD drop, but strong da Vinci 5 adoption and procedure growth may fuel a rebound.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available